Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses treatment with idelalisib for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL)
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses treatment with idelalisib for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL).
Clinical Pearls:
Pathologists Anticipate Evolving Role Using Allogeneic Cell Therapies
July 11th 2025Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the opportunities they present for patients and the potential challenges from a laboratory perspective.
Read More